Regeneron falls on forecast for 50% hike in Eylea sales; Pfizer wins EU nod for new Prevenar use;

@FiercePharma: Allergan eager to offload its obesity business (Lap-Band, etc) this quarter. PrivateEquity in on the hunt, CEO says. More | Follow @FiercePharma

@EricPFierce: Warburg Pincus' $195 million deal for JHP says something about the market for sterile injectable drugs. Story | Follow @EricPFierce

 @AlisonBFierce:  Rates of HPV-related cancers remain stubbornly high in the United States. More | Follow @AlisonBFierce

> A victim of its own success, Regeneron ($REGN) disappointed investors with predictions of 50% increases in sales of its Eylea drug for 2013, after reaching $838 million in 2012. Report

> Aiming to reach $2 billion in revenue, Cubist Pharmaceuticals ($CBST) will need to make its largest acquisition ever, because its pipeline isn't sufficient enough to boost sales to that level, analysts said. Report

> Pfizer ($PFE) nabbed a new European approval for its Prevenar 13 vaccine as a preventive for kids 6 to 17 years of age. Release | Report

> Allergan ($AGN) is eager to offload its obesity business by the end of the first quarter, CEO David Pyott said. Report

> Endo Health Solutions ($ENDP) and Pfizer each are paying $18.17 million to the state of Texas to settle allegations of Medicaid fraud. Report

> Novartis ($NVS) and Eisai have called it quits on their co-promotion agreement for three of Novartis' treatments for chronic obstructive pulmonary disease. Report

> Savient Pharmaceuticals ($SVNT) added Genzyme CEO David Meeker to its board of directors. Report

Medical Device News

 @FierceMedDev: JPM: T2 readies pivotal trial for Candida assay. Story | Follow @FierceMedDev

@MarkHFierce: A new NC startup wants to grow replacement corneas from donor cells and scaffolding. Story | Follow @MarkHFierce

 @DamianFierce: Fierce 15'er CardioKinetix is kicking off a pivotal trial for its heart-failure tech. Article | Follow @DamianFierce

> JPM: For med tech startups, fundraising hinges on establishing value. Report

> JPM: Medtronic's Ishrak promises more M&A, globalization. News

Biotech News

 @FierceBiotech: From FierceVaccines.com: India's vaccine prices soar as private companies gain ground. Story | Follow @FierceBiotech

@JohnCFierce: Sanofi's case for R&D turnaround includes a few setbacks for cancer, MS - coming up at JPM13 pipeline review. News | Follow @JohnCFierce

@RyanMFierce: Third Rock selling a preclinical stage portfolio company is interesting. It's TRV's 2nd exit, and they're gonna need wins to raise more $$. | Follow @RyanMFierce

> Boehringer tosses back rights to one of Lilly's key PhIII diabetes programs. News

> Bob Langer biotech lands first big biopharma deal with Amgen. Story

> Shire gambles on one-man biotech startup to gain ultra-orphan drug. Report

Pharma Manufacturing News

> Novartis finds blister packs sell more drugs. Story

> Lonza doubling ADC capacity at Visp. Report

> Malaysia's location, domestic market draw Ranbaxy, Cipla, others. Article

> Exela investing in North Carolina plant. News

Biotech Research News

> Mouse results unlock metformin's secrets. Story

> Addex preclinical drug slows inherited neuropathy. News

> Using gene therapy to fix a scarred heart. Report

> Cell transplant gives blind mice their sight back. Item

And Finally... A large new study found no links between antidepressants and stillbirths. Report

Suggested Articles

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.

Months after trial deaths prompted the FDA to halt study enrollment for AbbVie’s Venclexta, the agency will give the drug another shot.